对HER2低表达乳腺癌进行IHC检测，旨在评估观察者间的一致性，并分析其与数字成像的相关性。随着乳腺癌HER2三分类新时代的到来，HER2精准检测的重要性日益显著。而病理学家对HER2 ...

*仅供医学专业人士阅读参考研究深入探讨了IHC评分与mRNA表达在HER2低表达乳腺癌中的一致性，为精准诊断提供新视角。众所周知，针对人表皮生长因子受体2（HER2）的靶向治疗显著改善了HER2阳性乳腺癌患者的预后[1]，然而在缺乏该基因改变的患者中 ...

此前的 DESTINY-PanTumor02 临床研究已经证实了 T-DXd 对多种 HER 2 表达癌症的治疗效果和安全性，且发现肿瘤 HER 2 水平最高（免疫组化检测为 3+，即 IHC 3+）的患者治疗效果最佳。然而，此前研究中 HER 2 的检测是在中心实验室进行的，而在实际临床实践中，HER 2 检测更 ...

A real-world study showed HER2DX guided treatment changes in approximately 48% of HER2-positive breast cancer cases.

Trastuzumab, tested only as a single agent, has been shown to achieve 7% response in heavily pretreated patients with AOC with 3+ and 2+ HER2 immunostaining by immunohistochemistry (IHC).

HER2 IHC 3+ staining was observed in 15 (4.7%) of the 320 tumor samples analyzed and HER2 IHC 2+ in 26 (8.1%; Table 1). Low HER2 expression (IHC 0 or 1+) was detected in the 279 (87.2% ...